Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer

Pathology and Oncology Research

Volumn 17, Issue 2, 2011, Pages 325-332

  Szarvas, Tibor ^a   Jäger, Tobias ^a   Becker, Markus ^a   Tschirdewahn, Stephan ^a   Niedworok, Christian ^a   Kovalszky, Ilona ^b   Rübben, Herbert ^a   Ergün, Süleyman ^c   Vom Dorp, Frank ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Bladder cancer; Matrilysin; Metastasis; MMP 7; Plasma; Prognosis; Serum

Indexed keywords

MATRILYSIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CYSTECTOMY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN BLOOD LEVEL;

CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 7; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 80051668046     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-010-9320-4     Document Type: Article

References (24)

1. Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, Studer UE (2003) Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 21:690-696 (Pubitemid 46621904)
2. Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG (2006) Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 176:486-492 (Pubitemid 43927871)
3. vom Dorp F, Börgermann C, Schenck M, Becker M, Rose A, Szarvas T, Rübben H (2009) Role of lymphadenectomy in patients with invasive urothelial carcinoma of the bladder. Urologe 48:51-53
4. Dyrskjøt L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S, Knowles M, Malmström PU, de la Torre M, Wester K, Allory Y, Vordos D, Caillault A R F, Hein AM, Jensen JL, Jensen KM, Marcussen N, Orntoft TF (2007) Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res 13:3545-3551 (Pubitemid 46955114)
5. Szarvas T, Becker M, vom Dorp F, Gethmann C, Tötsch M, Bánkfalvi A, Schmid KW, Romics I, Rübben H, Ergün S (2010) Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci 101:1300-1308
6. Riley RD, Sauerbrei W, Altman DG (2009) Prognostic markers in cancer: the evolution of evidence from single studies to metaanalysis, and beyond. Br J Cancer 100:1219-1229
7. Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19:453-473 (Pubitemid 30126878)
8. Bleeker SE, Moll HA, Steyerberg EW, Donders AR, Derksen-Lubsen G, Grobbee DE, Moons KG (2003) External validation is necessary in prediction research: a clinical example. J Clin Epidemiol 56:826-832 (Pubitemid 37162656)
9. Werther K, Christensen IJ, Nielsen HJ, Danish RANX05 Colorectal Cancer Study Group (2002) Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 86:417-423 (Pubitemid 34185127)
10. Eble JN, Epstein JI, Sesterhenn I (2004) World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. IARCC Press, Lyon, pp 89-158
11. Jung K, Klotzek S, Stephan C, Mannello F, Lein M (2008) Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. Clin Chem 54:772-773
12. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM (1999) The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 9:1441-1447 (Pubitemid 30023478)
13. Noë V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M (2001) Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114:111-118 (Pubitemid 32120080)
14. Ito TK, Ishii G, Saito S, Yano K, Hoshino A, Suzuki T, Ochiai A (2009) Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood 113:2363-2369
15. Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD (1998) Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161:6845-6852 (Pubitemid 28562229)
16. Wang WS, Chen PM, Wang HS, Liang WY, Su Y (2006) Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis 27:1113-1120
17. Koskensalo S, Mrena J, Wiksten JP, Nordling S, Kokkola A, Hagström J, Haglund C (2010) MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol 31:149-155
18. Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, Mukaiya M, Hirata K, Imai K (2001) Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 19:1118-1127 (Pubitemid 32176289)
19. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT (1991) Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 117:144-150
20. Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, Mármol M, Gallardo E, Augé JM, Longarón R, Martínez-Fernandez A, Molina R, Castells A, Gascón P (2007) (2007) Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer 121:1066-1071 (Pubitemid 47101644)
21. Martínez-Fernandez A, García-Albeniz X, Pineda E, Visa L, Gallego R, Codony-Servat J, Augé JM, Longarón R, Gascón P, Lacy A, Castells A, Maurel J (2009) Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients. Ann Surg Oncol 16:1412-1420
22. Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Jung K (2008) Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas. Cancer Sci 99:1188-1194 (Pubitemid 351676631)
23. Szarvas T, Becker M, vom Dorp F, Meschede J, Scherag A, Bánkfalvi A, Henning R, Schmid KW, Romics I, Rübben H, Ergün S (2010) Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy Int J Cancer (In press)
24. Szarvas T, Singer BB, Becker M, vom Dorp F, Jäger T, Szendroi A, Riesz P, Romics I, Rübben H, Ergün S (2010) Urinary MMP-7 level is associated with the presence of metastasis in bladder cancer. BJU Int (In press)